Cellectis S.A. (EPA:ALCLS)
France · Delayed Price · Currency is EUR 3.440
+0.040 (1.18%)
At close: Feb 20, 2026
Cellectis Market Cap
Cellectis has a market cap or net worth of €248.8 million as of February 20, 2026. Its market cap has increased by 128.99% in one year.
Market Cap
248.80M
Enterprise Value
280.00M
Revenue
70.36M
Ranking
n/a
PE Ratio
n/a
Stock Price
€3.44
Market Cap Chart
Since February 7, 2007, Cellectis's market cap has increased from 100.59M to 248.80M, an increase of 147.33%. That is a compound annual growth rate of 4.87%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 20, 2026 | 248.80M | -18.00% |
| Dec 31, 2025 | 303.40M | 158.68% |
| Dec 31, 2024 | 117.29M | -40.86% |
| Dec 29, 2023 | 198.32M | 118.98% |
| Dec 30, 2022 | 90.57M | -73.23% |
| Dec 31, 2021 | 338.35M | -67.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Valneva SE | 825.33M |
| MedinCell | 790.50M |
| Genfit | 392.39M |
| Transgene | 225.09M |
| MaaT Pharma | 138.87M |
| Adocia | 137.15M |
| Innate Pharma | 131.78M |
| ABIONYX Pharma | 118.36M |